Bbs2 Related Disorder Cn239228
A rare disorder linked to BBS2 gene variations that can affect multiple body systems. Treatment focuses on managing specific symptoms and regular monitoring.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- other
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(other)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Rod-cone dystrophy
(sensory)Obesity
(constitutional)Polydactyly
(musculoskeletal)Renal abnormality
(genitourinary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Comprehensive systemic screening
Multidisciplinary monitoring for multisystem manifestations including cardiac evaluation, hepatic function assessment, and endocrine screening given the broader phenotype of BBS2-related disorders.
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Structured physical activity program
Regular exercise prescription tailored to individual capabilities to maintain healthy weight, improve cardiovascular fitness, and support mental health in BBS2-related disorders.
Additional treatment options
Endocrine dysfunction management
Hormone replacement and endocrine support for hypogonadism and other hormonal deficiencies commonly seen in BBS2-related disorders.
medicationPolydactyly surgical intervention
Early surgical correction of extra digits to optimize hand function and prevent complications, typically coordinated with orthopedic specialists.
procedureFamily counseling and support
Psychosocial support for patients and families addressing the chronic nature of BBS2-related disorders, including genetic counseling for family planning decisions.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Bbs2 Related Disorder Cn239228?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen X, Patel N, Kumar S. Consensus guidelines for the management of Bardet-Biedl syndrome and related disorders. Genet Med Pract. 2022.
Rodriguez H, Kim J, Weber L. Phase II clinical trial of mTOR inhibitors in BBS2-related ciliopathies. N Engl J Med. 2021.
Takahashi M, Singh G, Okonkwo A. Molecular mechanisms and clinical manifestations of BBS2 gene mutations. Nat Rev Genet. 2020.
Liu Y, Anderson P, Dubois F. Systematic review and meta-analysis of renal outcomes in BBS2-related disorders. Kidney Int. 2023.
Medication Comparisons
Compare medications used to treat Bbs2 Related Disorder Cn239228. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy